FDA approves Tzield for children with new stage 3 type 1 diabetes

The U.S. Food and Drug Administration has granted accelerated approval to Sanofi's Tzield (teplizumab-mzwv) to delay the decline in endogenous insulin production in children aged 8 to 17 years recently diagnosed with stage 3 type 1 diabetes.